---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-007042"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:20:37.860230+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ra Medical delays Q1 10-Q filing; cites acquisition accounting issues, goodwill write-off expected

## Summary
- Company will not file Q1 2023 10-Q by deadline; no exact filing date projected.
- Delay due to auditor review of Catheter Precision acquisition accounting, including Series X preferred stock valuation.
- Projects Q1 2023 revenue of ~$85,000; expects all or substantially all goodwill to be written off.
- Decline in RMED stock price since Jan 9 acquisition date caused decline in value of acquired assets under review.

## SEC filing metadata
- accession: 0001654954-23-007042
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/0001654954-23-007042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/rmed_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-007042
- JSON: https://secwatch.observer/filing/0001654954-23-007042.json
- Plain text: https://secwatch.observer/filing/0001654954-23-007042.txt

## Key facts
- Earnings Releases
  Catheter Precision, Inc. reported the quarter ended March 31, 2023 results: revenue approximately $85,000.
  - Period: the quarter ended March 31, 2023
  - Revenue: approximately $85,000
  - Result: preliminary results
  source text: The Company continues to project revenues for the quarter ended March 31, 2023 of approximately $85,000, and also projects that all or substantially all of its goodwill will be written off as a result of the finalization of the purchase price allocation in connection with the Company’s merger with Catheter Precision, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/0001654954-23-007042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.